A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Minnesota Rubber and Plastics Acquires Primasil Silicones Ltd.

Quadion LLC, d.b.a. Minnesota Rubber and Plastics (MRP), a leading provider of highly engineered elastomer and thermoplastic solutions for the medical, water and specialty industrial end markets, announced today its acquisition of Primasil Silicones Ltd. (Primasil), a Weobley, U.K.-based custom silicone rubber compounder, mixer and manufacturer specializing in the medical, HVAC and specialty industrial end markets.

“We’re thrilled to add Primasil, a company with four decades of silicone materials science expertise, to our family. Primasil’s custom material formulation, mixing and molding expertise will complement Minnesota Rubber and Plastic’s renowned materials science and molding capabilities. It will also provide a wide variety of new solutions for our clients,” said Jay Ward, CEO of Minnesota Rubber and Plastics.

Ward noted, “We have a long history of successfully serving our customers in Europe, and the addition of a highly technical production presence in the U.K. and Czech Republic will allow us to take our local capabilities to the next level. Not only will the acquisition augment our materials science and manufacturing capabilities, but it will also expand our global scope – particularly in the medical end market – and further our plans to expand our European footprint while we actively look to partner and acquire technical elastomer companies across the region.”

Primasil offers a wide range of custom materials, including platinum-cured silicone, conductive silicone, flourosilicone, high- and low-temperature silicone, low smoke and toxicity silicone and black rubber. Primasil’s proprietary silicone expertise will contribute to MRP’s materials science-driven Innovation Center, launching Spring 2022.

Furthermore, Primasil’s high precision manufacturing capabilities include cleanroom molding, extrusion and assembly as well as mixing, injection molded and proprietary gum silicone and liquid silicone rubber (LSR) products.

The addition of Primasil’s capabilities will complement MRP’s existing offerings, which include highly engineered elastomer and thermoplastic solutions for the medical device, water, food and beverage, infrastructure and other essential industries globally. MRP built its strong reputation over its more than 75-year history for designing, developing, manufacturing and assembling products for harsh environments, tight tolerances and technically demanding applications, including multi-material solutions and custom material formulations.

“The Primasil team is extremely excited about this opportunity. We look forward to working alongside our new colleagues at Minnesota Rubber and Plastics to continue serving our valued customers – in Europe and around the globe – with innovative technologies, great talent and more options than ever before,” said Steve Wheeler, Managing Director of Primasil. “We’re not just acquiring great products and capabilities to complement our current offerings; we’re adding a world-class team. We plan to extend ownership to all of the new colleagues we welcome onboard from Primasil,” added Ward.

Wheeler will continue to lead Primasil, reporting into the MRP organization. For more information about Minnesota Rubber and Plastics and its current offerings.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy